Tenders Are Invited For Durvalumab (Genetical Recombination) (500Mg 10Ml/Vial) 90 Vials

Tenders are invited for Durvalumab (Genetical Recombination) (500mg 10ml/Vial) 90 Vials Official in Charge of Disbursement of the Procuring Entity : Houkin Kiyohiro, President, The National University Corporation Hokkaido University Classification of the Products to be Procured : 4 Nature and Quantity of the Products to be Purchased : Durvalumab (Genetical Recombination) (500mg 10ml/Vial) 90 Vials Delivery Period : From 1 October, 2024 through 31 may, 2025 Delivery Place : Hokkaido University Hospital Qualifications for Participating in the Tendering Procedures : Suppliers Eligible for Participating in the Proposed Tender are Those Who shall : A have the Grade a, Grade B, Grade C or Grade D Qualification during Fiscal 2024 in the Hokkaido Area in Sales of Products for Participating in Tenders by Single Qualification for Every Ministry and Agency, Or in Tenders by Hokkaido University, B Prove to have Obtained the Wholesale Distribution License for Selling Pharmaceuticals in Accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, C Prove to have the Ability to Deliver the Products, Required by this Notice, On the Date and to the Place Specified by the President, D not be Currently under a Suspension of Business Order as Instructed by the President, The National University Corporation Hokkaido University. Time Limit of Tender : 17 : 00 25 September, 2024 Contact Point for the Notice : Tobioka Naoki, Medicine Section, Financial Division, Hokkaido University Hospital, Kita 14 Nishi 5 Kita-Ku Sapporo-Shi 060-8648 Japan, Tel 011-706-7405 Please be Noted that if it is Indicated that Environmental Conditions Relating to the Procurement are Laid down in its Tender Documents. Tender Link : https://www.jetro.go.jp/en/database/procurement/national/articles/323691/2024080500290000.html